REVIEW article
Front. Vet. Sci.
Sec. Oncology in Veterinary Medicine
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1593333
This article is part of the Research TopicNew Insights in Veterinary Cancer Immunology Volume IIView all 4 articles
Human Immuno -Therapeutics for Cancer Treatment of Dogs ?
Provisionally accepted
- ImmunityBio, Inc., Culver City, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Immunotherapy for humans has enjoyed a recent boost of treatment options that, however, has not translated into the veterinary field. Developments like monoclonal antibodies against immune checkpoint inhibitors and tumor-specific CAR-T cells have broadened treatment options for human cancer patients but the canine space has not benefited from those advancements. These novel treatments are expensive to develop for the canine market and are not necessarily promising a significant financial return for the pharmaceutical industry. Hence the question is whether there are immunotherapies that work for humans and that also have some cross-species (xenogeneic) activity in dogs, but at the same time have only minimal side effects and are affordably priced. Can such an approach be considered at all assuming that the disparity could result in an immediate rejection of the administered 'product' with all the potential side effects ? Maybe this assumption is not necessarily founded on solid data and this brief review attempts to summarize of what is actually known on the treatment of canine cancers with human immuno-therapeutics.
Keywords: Immunotherapy,, Dogs,, NK cells, Lymphocytes, Crossreactivity
Received: 13 Mar 2025; Accepted: 17 Jun 2025.
Copyright: © 2025 Klingemann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hans Klingemann, ImmunityBio, Inc., Culver City, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.